Puel A

Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.

Gervais A, Marchal A, Boucherit S, ..., Casanova JL, Jouanguy E

J. Exp. Med. 223 (3) - [2026-03-02; online 2025-12-05]

Evaluating IL1RA-Autoantibodies Across SARS-CoV-2-Related Diseases.

Behere A, Hallberg P, Cederholm A, ..., Brodin P, Landegren N

Scand. J. Immunol. 102 (1) e70039 [2025-07-00; online 2025-06-25]

Human LY9 governs CD4+ T cell IFN-γ immunity to Mycobacterium tuberculosis.

Ogishi M, Puchan J, Yang R, ..., Boisson-Dupuis S, Casanova JL

Sci Immunol 10 (107) eads7377 [2025-05-30; online 2025-05-30]

Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.

Rosain J, Le Voyer T, Liu X, ..., Anderson MS, Casanova JL

J. Exp. Med. 221 (11) - [2024-11-04; online 2024-10-01]

Inherited human RelB deficiency impairs innate and adaptive immunity to infection.

Le Voyer T, Maglorius Renkilaraj MRL, Moriya K, ..., Tangye SG, Puel A

Proc. Natl. Acad. Sci. U.S.A. 121 (37) e2321794121 [2024-09-10; online 2024-09-04]

Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency.

Le Voyer T, Parent AV, Liu X, ..., Casanova JL, Puel A

Nature 623 (7988) 803-813 [2023-11-00; online 2023-11-08]

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Bastard P, Rosen LB, Zhang Q, ..., Su HC, Casanova JL

Science (New York, N.Y.) 370 (6515) - [2020-10-23; online 2020-09-24]